Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AbCellera Biologics Inc. (ABCL)
|
Add to portfolio |
|
|
|
| Price: |
$13.27
| | Metrics |
| OS: |
289.4
|
M
| |
|
|
| Market cap: |
$3.84
|
B
| |
|
|
|
Net cash:
|
$239
|
M
| |
$0.82
|
per share
|
|
EV:
|
$3.6
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Revenues | 485.4 | 375.2 | 233.2 | 11.6 | |
| Revenue growth | 29.4% | 60.9% | 1907.9% | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross profit | 485.4 | 375.2 | 233.2 | 11.6 | |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | |
| Sales and marketing | 11.3 | 6.9 | 3.8 | 1.3 | |
| Research and development | 107.9 | 62.1 | 29.4 | 10.1 | |
| General and administrative | 55.5 | 41.8 | 11.9 | 2.7 | |
| EBITA | 227.0 | 214.5 | 158.5 | -4.1 | |
| EBITA margin | 46.8% | 57.2% | 68.0% | -35.5% | |
| Amortization of intangibles | 10.5 | 10.1 | 2.5 | | |
| EBIT | 216.5 | 204.4 | 156.0 | -4.1 | |
| EBIT margin | 44.6% | 54.5% | 66.9% | -35.5% | |
| Pre-tax income | 239.1 | 219.1 | 157.8 | -2.2 | |
| Income taxes | 80.6 | 65.7 | 38.9 | 0.0 | |
| Tax rate | 33.7% | 30.0% | 24.7% | 0.0% | |
| Net income | 158.5 | 153.5 | 118.9 | -2.2 | |
| Net margin | 32.7% | 40.9% | 51.0% | -19.0% | |
| |
| Diluted EPS | $0.50 | $0.48 | $0.45 | ($0.01) | |
| Shares outstanding (diluted) | 314.8 | 318.3 | 263.1 | 151.3 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|